Navigation Links
In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market
Date:3/7/2008

NEW YORK, March 7 /PRNewswire/ -- The rheumatoid arthritis (RA) treatment market, held back somewhat in recent years by generic competition and the withdrawal of Vioxx and Bextra, is rebounding due to the performance of biologic treatments. The market for prescription drugs to treat RA topped $12 billion in 2006 and -- driven by new immunosupressants and other biologics -- will increase over 11% a year through 2011, according to a new report by Kalorama Information, Worldwide Market for Rheumatoid Arthritis and Lupus Treatments.

Autoimmune diseases are some of the most difficult conditions to treat, with RA topping the list. Worldwide, more than 39 million people suffer from RA and drug developers are scrambling to understand the underlying causes and find new treatments.

The availability and increased use of biologic treatments such as Enebrel, Rituxan and Remicade, representing three-quarters of the RA market in 2006, has revived growth in the industry, offsetting declines for older non- steroidal anti-inflammatory drug (NSAID) treatments, which tend to have more generic competition. Sales of biologic treatments will grow 85% by 2011, according to Kalorama Information.

The most common biologic approaches to RA involve immunosupressant drugs that block three actors in the immune system: T-cells, chemical messengers, and white blood cells. There are also novel new therapies that activate suppresser cells, inhibiting the production of inflammation enzymes, suppressing the production of inflammation agents, and preventing the production of B-cell antibodies.

"Any drug market would suffer from having the world's most well-known drug withdrawal, but biologics are changing the story," says Bruce Carlson, Publisher of Kalorama Information. "They've shown better results than the standard treatments and, in the near-term at least, they won't have competition from generics. They will represent the lion's share of growth in the market."

Kalorama Information's report Worldwide Market for Rheumatoid Arthritis and Lupus Treatments analyzes the current and potential world market and opportunities for prescription drugs to treat RA and Lupus. The information presented is the result of interviews conducted with over 60 industry executives, as well as data gathered through secondary research. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Worldwide-Rheumatoid-Arthritis-1399498/

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AstraZeneca - Biologics Day Interviews With Senior Management
2. Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
3. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
4. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
5. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
6. Hospitals and the Coalition to Protect Floridas Drivers Applaud Lawmakers for Reviving No-Fault Insurance
7. Rheumatoid Arthritis Drugs May Lower Heart Attack, Stroke Risk
8. Study of 137 Meniscus Transplant Procedures in Patients with Arthritis is Presented to the Meniscus Transplantation Study Group at the American Academy of Orthopaedic Surgeons Annual Meeting
9. Misdiagnosis of rheumatoid arthritis
10. Common Rheumatoid Arthritis Drug Wont Raise Blood Cancer Risk
11. MultiVu Video Feed: LIFE AND STYLE EXPERT SANDRA LEE OFFERS RECIPES AND SHORTCUTS IN THE KITCHEN TO PEOPLE WITH RHEUMATOID ARTHRITIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES ... has announced that Mercy Medical Center will serve as the official title sponsor of ... On Sunday, June 25, 2017, thousands of women will walk or run the course ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... several educational opportunities for attending prescribers at the upcoming World Congress, in Hollywood ... “A4M has always been recognized as the visionary leader in the training of ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... in Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. ... to traditional orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES ...
(Date:3/29/2017)... ... 2017 , ... Altima Technologies, Inc., the maker of popular ... assets and audio-video devices has recently updated its Visio Stencils library with new ... download shapes and stencils from http://www.VisioStencils.com. , New devices were added ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly ... assembly protocols involve many repetitive steps and often scientists require many different versions ... high-throughput needed, and results in a lower error rate and cost saving for ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has announced ... Patients Treated at Proton Therapy Centers & Forecast" report to their ... The South Korean ... current market size in 2016. The Untapped Proton Therapy Market for ... USD in 2016. Proton Therapy plays an important role ...
(Date:3/29/2017)... 29, 2017  The leader in accelerated orthodontics, OrthoAccel ... Sam Daher , Manal Ibrahim , Kenji ... will be the featured microlecture presenters at the AcceleDent ... of Orthodontists (AAO) Annual Session, April 21-25, 2017. Orthodontists ... beginning daily at 11:20 a.m. On the opening morning ...
(Date:3/29/2017)... 2017  Maxor National Pharmacy Services, LLC ("Maxor"), a ... named Leah Bailey as General Counsel.  Bailey will ... company. With more than 13 years of ... focused on health care, Bailey joins the Maxor team ... Bailey advised the PBM, Specialty, and Mail Order business ...
Breaking Medicine Technology: